固体脂质纳米粒药物载体在肿瘤治疗中应用的研究进展

doi:10.13481/j.1671-587x.20200135

摘要/Abstract

摘要： 肿瘤治疗以手术治疗为主，辅助以化疗、放疗和生物治疗，其中化疗起着重要的作用。但在肿瘤化疗中化疗药物缺乏靶向性，对人体正常组织和器官有一定的不良反应。为克服这一问题研究者开发了药物载体，目前固体脂质纳米粒（SLN）已成为在肿瘤治疗中有应用前景的纳米载体。作为新一代亚微粒给药系统，SLN是以毒性低、生物相容性好、生物可降解的固态天然或合成的类脂为载体，将药物吸附或包裹于脂质膜中而制成的，具有可搭载多种药物、药物生物利用度高、延缓药物释放和多种给药途径等优点，并通过靶向作用提高对不同类型肿瘤的治疗效果，广泛应用于乳腺癌、肺癌、结直肠癌、肝癌和脑癌等疾病的治疗中。现从SLN药物载体的制备方法、载体优势、给药途径以及在肿瘤治疗中的应用等几方面进行综述。

关键词: 固体脂质纳米粒, 药物载体, 肿瘤, 靶向治疗

中图分类号:

O631.1

栗达, 贾颜鸿, 周童, 王欣琦, 张泽兵. 固体脂质纳米粒药物载体在肿瘤治疗中应用的研究进展[J]. 吉林大学学报(医学版), 2020, 46(01): 200-204.

参考文献

[1] ZHAO S N, MINH L V, LI N, et al. Doxorubicin hydrochloride-oleic acid conjugate loaded nanostructured lipid carriers for tumor specific drug release[J]. Colloids Surf B Biointerfaces, 2016, 145:95-103.
[2] TAPEINOS C, BATTAGLINI M, CIOFANI G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases[J]. J Control Release, 2017, 264:306-332.
[3] PATIL A, LAKHANI P, TASKAR P, et al. Formulation development, optimization, and in vitro-in vivo characterization of natamycin-loaded PEGylated nano-lipid carriers for ocular applications[J]. J Pharm Sci, 2018, 107(8):2160-2171.
[4] BANGHAM A D, HORNE R W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope[J]. J Mol Biol, 1964, 8:660-668.
[5] KUMAR M, KAKKAR V, MISHRA A K, et al. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood[J]. Int J Pharm, 2014, 461(1/2):223-233.
[6] MU H L, HOLM R. Solid lipid nanocarriers in drug delivery:characterization and design[J]. Expert Opin Drug Deliv, 2018, 15(8):771-785.
[7] MVLLER R H, MAASSEN S, WEYHERS H, et al. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407[J]. J Drug Target, 1996, 4(3):161-170.
[8] DARA T, VATANARA A, NABI MEYBODI M, et al. Erythropoietin-loaded solid lipid nanoparticles:Preparation, optimization, and in vivo evaluation[J]. Colloids Surf B Biointerfaces, 2019, 178:307-316.
[9] DU B, YAN Y, LI Y, et al. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles[J]. Pharm Dev Technol, 2010, 15(4):346-353.
[10] WANG W, ZHAO X L, HU H Y, et al. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability[J]. Drug Deliv, 2010, 17(3):114-122.
[11] NATARAJAN J, BASKARAN M, HUMTSOE L C, et al. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles[J]. Artif Cells Nanomed Biotechnol, 2017, 45(2):364-371.
[12] 卫聪聪. SLN聚集动力学及其提高药物口服生物利用度研究[D]. 天津:天津大学, 2012.
[13] 王安斌, 张渊, 张艳, 等. 纳米碳酸钙及脂质体包覆提高淫羊藿苷生物利用度的研究[J]. 中华中医药学刊,2017, 35(7):1860-1863.
[14] RAMESH N, MANDAL A K A. Pharmacokinetic, toxicokinetic, and bioavailability studies of epigallocatechin-3-gallate loaded solid lipid nanoparticle in rat model[J]. Drug Dev Ind Pharm, 2019, 45(9):1506-1514.
[15] JOSHI M D, MVLLER R H. Lipid nanoparticles for parenteral delivery of actives[J]. Eur J Pharm Biopharm, 2009, 71(2):161-172.
[16] WANG F, LI L, LIU B, et al. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer[J]. Biomed Pharmacother, 2017, 86:595-604.
[17] SHAZLY G A, ALSHEHRI S, IBRAHIM M A, et al. Development of domperidone solid lipid nanoparticles:In vitro and in vivo characterization[J]. AAPS Pharm Sci Tech, 2018, 19(4):1712-1719.
[18] FONSECA-SANTOS B, SILVA P B, RIGON R B, et al. Formulating SLN and NLC as innovative drug delivery systems for non-invasive routes of drug administration[J]. Curr Med Chem, 2019,26:1-33.
[19] GRASSIN-DELYLE S, BUENESTADO A, NALINE E, et al. Intranasal drug delivery:An efficient and non-invasive route for systemic administration:focus on opioids[J]. Pharmacol Ther, 2012, 134(3):366-379.
[20] GANGURDE P K, AJITKUMAR B N, KUMAR L. Lamotrigine lipid nanoparticles for effective treatment of epilepsy:A focus on brain targeting via nasal route[J]. J Pharm Innov, 2019, 14(2):91-111.
[21] TALEGAONKAR S, BHATTACHARYYA A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability[J]. AAPS Pharm Sci Tech, 2019, 20(3):121.
[22] RADWAN A, EL-LAKKANY N M, WILLIAM S, et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection[J]. Parasit Vectors, 2019, 12(1):304.
[23] AKBARI J, SAEEDI M, MORTEZA-SEMNANI K, et al. The design of naproxen solid lipid nanoparticles to target skin layers[J]. Colloids Surf B Biointerfaces, 2016, 145:626-633.
[24] ROSTAMKALAEI S S, AKBARI J, SAEEDI M, et al. Topical gel of metformin solid lipid nanoparticles:a hopeful promise as a dermal delivery system[J]. Colloids Surf B Biointerfaces, 2019, 175:150-157.
[25] PUGLIA C, BLASI P, RIZZA L, et al. Lipid nanoparticles for prolonged topical delivery:An in vitro and in vivo investigation[J]. Int J Pharm, 2008, 357(1/2):295-304.
[26] XU W T, BAE E J, LEE M K. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells[J]. Int J Nanomedicine, 2018, 13:7549-7563.
[27] XU P F, YIN Q, SHEN J N, et al. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS[J]. Int J Pharm, 2013, 454(1):21-30.
[28] DOKTOROVOVA S, SOUTO E B, SILVA A M. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines[J]. Pharm Dev Technol, 2018, 23(1):96-105.
[29] JIANG S, ZHU R R, HE X L, et al. Enhanced photocytotoxicity of curcumin delivered by solid lipid nanoparticles[J]. Int J Nanomed, 2017, 12:167-178.
[30] AKBABA G E, AKBABA H, KANTARCI A G. Development and in vitro evaluation of positive-charged solid lipid nanoparticles as nucleic acid delivery system in glioblastoma treatment[J]. Marmara Pharm J, 2018, 22(2):299-306.
[31] 李万玉, 晏子俊, 孙立力, 等. 姜黄素固体脂质纳米粒在大鼠体肠中吸收的研究[J]. 食品与生物技术学报,2017, 36(7):733-737.
[32] CHIRIO D, PEIRA E, BATTAGLIA L, et al. Lipophilic prodrug of floxuridine loaded into solid lipid nanoparticles:in vitro cytotoxicity studies on different human cancer cell lines[J]. J Nanosci Nanotechnol, 2018, 18(1):556-563.
[33] SERINI S, CASSANO R, CORSETTO P A, et al. Omega-3 PUFA loaded in resveratrol-based solid lipid nanoparticles:physicochemical properties and antineoplastic activities in human colorectal cancer cells in vitro [J]. Int J Mol Sci, 2018, 19(2):E586.
[34] GRILLONE A, RIVA E R, MONDINI A, et al. Active targeting of sorafenib:preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles[J]. Adv Healthc Mater, 2015, 4(11):1681-1690.
[35] RODENAK-KLADNIEW B, ISLAN G A, DE BRAVO M G, et al. Design, characterization and in vitro evaluation of linalool-loaded solid lipid nanoparticles as potent tool in cancer therapy[J]. Colloids Surf B Biointerfaces, 2017, 154:123-132.
[36] 曹越盛, 郭英雪, 于莲, 等. 黄芩苷固体脂质纳米粒的药代动力学和体外对肝癌细胞生长研究[J]. 黑龙江医药科学,2017, 40(3):53-56.
[37] 陈娇婷, 叶民珠. 蛇床子素固体脂质纳米粒的体内抗肿瘤活性研究[J]. 中国民族民间医药,2016, 25(17):22-24.
[38] RAHIMINEJAD A, DINARVAND R, JOHARI B, et al. Preparation and investigation of indirubin-loaded SLN nanoparticles and their anti-cancer effects on human glioblastoma U87MG cells[J]. Cell Biol Int, 2019, 43(1):2-11.
[39] EREL-AKBABA G, CARVALHO L A, TIAN T, et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy[J]. ACS Nano, 2019, 13(4):4028-4040.
[40] 刘斌亮,马飞.肿瘤治疗与血脂代谢异常[J].中国实用内科杂志,2018,38(7):599-603.
[41] 易衡静,张亮,王志刚,等.靶向肿瘤细胞的相变型纳米粒多模态显像及其声动力治疗的体外实验研究[J].解放军医学杂志,2018,43(10):822-827.